Select Page

NY Bio-Computation Startup EVQLV Closes Financing Round

Feb 8, 2021 | Press Releases | 0 comments

Alexander Sonneborn

NEW YORK, February 8, 2021 — EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development and scaling of its technology, and expand commercial efforts.

Based in New York City, EVQLV combines the latest advances in machine learning with massive amounts of biological data in order to accelerate the discovery and development of biologics, with a current focus on antibodies. Andrew Satz, CEO of EVQLV said “Our near-term goals are to deepen our relationships with our partners, execute on a dozen lab experiments, engage with innovative and forward-thinking companies, build additional technical innovations and capacity, and continue our rapid growth trajectory.”

“This funding will allow our incredible team to focus our efforts on achieving technical, scientific, and commercial milestones over the coming months” Satz continues. “Our achievements to date are a testament to the determination and agility of our team and the support of our partners. We are incredibly fortunate to be joined by this group of investors, whose skills and experience can aid in our mission of accelerating the speed that healing reaches those in need.”


‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...